Buy & Sell Williams Companies Inc (WMB) – Williams Companies Inc Price Today
Aura AI Summary
Key Stats
- $95.01BMarket Cap
- EnergySector
- -7.64%3M Drawdown
- $124.40BEnterprise Value
- 2.7%Dividend Yield
- 100% Buy | 0% SellTrading Activity
- 54 daysTypical Hold Time
Williams Companies Inc (WMB) is currently valued at a market capitalization of $95.01B, with an enterprise value of $124.40B. Over the past 52 weeks, Williams Companies Inc has traded between a low of $56.51 and a high of $79.48, highlighting its annual price range. Over the past three months, Williams Companies Inc has recorded a drawdown of -7.64%, reflecting recent price volatility. Williams Companies Inc offers a dividend yield of 2.7%, with the most recent dividend of $0.53 paid on 13 Mar 26. On average, investors hold Williams Companies Inc for approximately 54 days, indicating typical investor behavior on the platform.
About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Most Recent News
Short seller warns Everspin stock is overvalued amid AI hype, predicts 60% downside.
Kerrisdale Capital has taken a short position on Everspin Technologies, arguing the recent surge in its stock price is driven by misplaced enthusiasm around AI-related memory demand. Everspin's MRAM technology targets niche industrial markets rather ...

Vuzix showcases advanced waveguide smart glasses for defense at SOF Week 2026 in Florida
Vuzix Corporation is exhibiting its advanced AI-powered smart glasses and waveguide solutions at SOF Week 2026 in Tampa, Florida. These products are designed for defense use, offering mission-ready optical performance in challenging environments, inc...

Over 50 companies advance 55+ new pulmonary arterial hypertension drugs in clinical trials.
More than 50 companies are actively developing over 55 new drugs for pulmonary arterial hypertension (PAH), a serious lung-related heart condition. These drugs are in various clinical trial stages, with several in late-stage development, aiming to im...
